X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (871) 871
Book Review (153) 153
Publication (56) 56
Book / eBook (6) 6
Book Chapter (4) 4
Magazine Article (3) 3
Newspaper Article (3) 3
Conference Proceeding (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (754) 754
index medicus (743) 743
ophthalmology (581) 581
male (398) 398
female (380) 380
middle aged (308) 308
aged (284) 284
macular edema - chemically induced (226) 226
macular edema - drug therapy (226) 226
macular degeneration (205) 205
animals (160) 160
fluorescein angiography (160) 160
glucocorticoids - adverse effects (159) 159
injections (154) 154
tomography, optical coherence (151) 151
adult (144) 144
aged, 80 and over (141) 141
macular edema (141) 141
intraocular pressure - drug effects (139) 139
vitreous body (135) 135
visual acuity (131) 131
retrospective studies (130) 130
triamcinolone acetonide - adverse effects (129) 129
eye diseases (125) 125
intravitreal injections (125) 125
abridged index medicus (119) 119
bevacizumab (116) 116
macular edema - diagnosis (115) 115
diabetic retinopathy (114) 114
cystoid macular edema (108) 108
glaucoma (104) 104
ocular hypertension - chemically induced (102) 102
vascular endothelial growth factor a - antagonists & inhibitors (102) 102
risk factors (93) 93
angiogenesis inhibitors - adverse effects (92) 92
diabetic macular edema (89) 89
glucocorticoids - administration & dosage (86) 86
diabetic retinopathy - drug therapy (83) 83
follow-up studies (83) 83
pharmacology & pharmacy (83) 83
triamcinolone (83) 83
vascular endothelial growth factor (83) 83
retina (81) 81
endothelial growth-factor (78) 78
surgery (74) 74
treatment outcome (74) 74
diabetes (72) 72
edema (69) 69
macular edema - etiology (69) 69
injection (68) 68
ranibizumab (67) 67
care and treatment (66) 66
macular degeneration - drug therapy (65) 65
triamcinolone acetonide - administration & dosage (65) 65
antibodies, monoclonal, humanized (62) 62
complications and side effects (62) 62
intraocular pressure (62) 62
optical coherence tomography (62) 62
prospective studies (61) 61
retinal vein occlusion (61) 61
triamcinolone acetonide (60) 60
medicine & public health (59) 59
retinopathy (59) 59
visual acuity - drug effects (59) 59
genetic structures (57) 57
retina - drug effects (57) 57
angiogenesis inhibitors - administration & dosage (56) 56
drug therapy (56) 56
macular edema - physiopathology (56) 56
retinal diseases - chemically induced (55) 55
sense organs (55) 55
corticosteroids (53) 53
neovascularization (53) 53
antibodies, monoclonal - adverse effects (52) 52
glucocorticoids - therapeutic use (52) 52
research (52) 52
therapy (52) 52
uveitis (52) 52
cataract - chemically induced (51) 51
prostaglandins f, synthetic - adverse effects (50) 50
safety (49) 49
inflammation (48) 48
eye (47) 47
choroidal neovascularization (46) 46
fundus oculi (46) 46
vitrectomy (45) 45
angiogenesis (44) 44
choroidal neovascularization - drug therapy (44) 44
disease models, animal (43) 43
visual acuity - physiology (43) 43
dosage and administration (42) 42
drug implants (42) 42
intravitreal injection (42) 42
retina - pathology (42) 42
intraocular-pressure (41) 41
rabbits (41) 41
triamcinolone acetonide - therapeutic use (40) 40
analysis (39) 39
antihypertensive agents - adverse effects (39) 39
endophthalmitis - chemically induced (39) 39
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (841) 841
French (15) 15
German (14) 14
Spanish (8) 8
Japanese (5) 5
Portuguese (2) 2
Hebrew (1) 1
Polish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2010, Volume 362, Issue 5, pp. 387 - 401
In this 24-month, randomized trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod reduced the rates of relapse and disability... 
IMMUNE | SPHINGOSINE 1-PHOSPHATE RECEPTORS | MEDICINE, GENERAL & INTERNAL | FTY720 | CENTRAL-NERVOUS-SYSTEM | PHASE-II EXTENSION | AGONISTS | Arrhythmias, Cardiac - chemically induced | Herpesviridae Infections - etiology | Sphingosine - adverse effects | Herpesviridae Infections - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Young Adult | Propylene Glycols - adverse effects | Sphingosine - administration & dosage | Propylene Glycols - therapeutic use | Adult | Female | Immunosuppressive Agents - administration & dosage | Disability Evaluation | Liver Function Tests | Multiple Sclerosis, Relapsing-Remitting - pathology | Macular Edema - chemically induced | Double-Blind Method | Administration, Oral | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Kaplan-Meier Estimate | Fingolimod Hydrochloride | Disease Progression | Magnetic Resonance Imaging | Sphingosine - analogs & derivatives | Propylene Glycols - administration & dosage | Adolescent | Brain - pathology | Immunosuppressive Agents - adverse effects | Sphingosine - therapeutic use | Multiple sclerosis | Usage | Magnetic resonance imaging | Placebos | Dosage and administration | Diagnosis | Drug therapy | Comparative analysis | Immunosuppressive agents | Interferon | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 03/2018, Volume 187, pp. 138 - 147
Journal Article
Journal of the Neurological Sciences, ISSN 0022-510X, 2012, Volume 323, Issue 1, pp. 167 - 172
Journal Article
OPHTHALMOLOGE, ISSN 0941-293X, 05/2018, Volume 115, Issue 5, pp. 424 - 428
Background. Fingolimod, a disease-modifying sphingosine 1-phosphate receptor modulator, which was approved in Germany in 2011, decreases the relapse rate and... 
Multiple sclerosis | FAME | ORAL FINGOLIMOD | Fingolimod | MULTIPLE-SCLEROSIS | Acetazolamide | OPHTHALMOLOGY | Macular edema | Macular Edema - chemically induced | Immunosuppressive Agents | Multiple Sclerosis, Relapsing-Remitting | Humans | Middle Aged | Female | Fingolimod Hydrochloride - adverse effects | Germany
Journal Article